An interventional study of Rapid 30-minute Desktop Assay in Urethritis, Cervicitis and Sexually Transmitted Infections, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 207th largest by enrollment of the 251 interventional ones that give a count, is one of 14 that started in 2023, is one of 190 with no phase, and was the 231st registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
Westat · Sites in United States
Ages 13–24 · Men only · Healthy volunteers
Emory University · Sites in United States
Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 13–21 · Men only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 15 · Phase 4 12
First in 1993; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is below the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Median enrollment 400 across the 251 interventional studies, 280 across the 30 observational. Of the 227 that completed or were terminated, 76 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 283 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 3 studies filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
16 of the studies in Sexually Transmitted Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06183502Emory UniversityHIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men | 2026-11 |
| NCT07089836American Laboratory Products CompanyThis Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests. | 2026-12 |
| NCT07281599QurasenseEvaluation of the Q-Pad hrHPV Test System for Identifying Precancer | 2026-12-31 |
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT04372875Children's National Research InstituteHealth Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a pilot randomized controlled trial evaluating the use of either a) rapid 30-minute desktop assay or b) point-of-care gram stain (current standard of care) to guide the clinical management of patients with symptomatic urethritis or cervicitis evaluated in the Massachusetts General Hospital Sexual Health Clinic. Patients presenting with symptoms of urethritis or cervicitis and meeting inclusion criteria will be randomized to have diagnostic specimens tested during the clinical encounter using either the 30-minute desktop assay or point-of-care gram stain. Patients randomized to the intervention arm of the study will also have a gram stain created, which will be held for interpretation by the clinician following the clinical encounter. Patients will not be followed longitudinally. Recruitment will conclude when 100 participants enroll in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Point-of-care gram stain
Diagnostic Test: Rapid 30-minute Desktop Assay
Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter. Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay. Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols.
Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis
The investigators will compare the mean antibiotic days of therapy (DOT) administered per patient at the time of initial ciinical visit when evaluated with either point-of-care gram stain or rapid 30-minute desktop test.
Time frame: Day 1
Participant Visit Duration
The investigators will compare visit duration between participants randomized to the point-of-care test and those to the 30-minute desktop test. Participant visit duration will be calculated as the difference between when the participant enters the exam room and when they check out of the clinic, in minutes.
Time frame: Day 1
Sample Processing Time
The investigators will compare the time taken to process clinical specimen using either the point-of-care gram stain or rapid 30-minute desktop test. The provider processing the samples will record the start and end times on a time sheet, and the sample processing time will be calculated as the difference between those entries, in minutes.
Time frame: Day 1
Time to Result
The investigators will compare time from specimen collection to availability of test result between the point-of-care gram stain or rapid 30-minute desktop test. Providers will record time of specimen collection and time of result (for point of care gram stain), time of result for the rapid desktop platform will be extracted from the platform; time to result will be calculated as the difference between those times, in minutes.
Time frame: Day 1
Test-concordant Antibiotic Use for Gonorrhea
Proportion of participants in each arm who recevied gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was positive for gonorrhea, or who did not receive gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was negative for gonorrhea
Time frame: Day 1
Diagnosis-concordant Antibiotic Use for Gonorrhea
Proportion of participants in each arm who were prescribed an antibiotic with activity against gonorrhea on the day of clinic visit, either for a positive test result or for a clinical syndrome for which the antibiotics are indicated (e.g., a clinical diagnosis of pelvic inflammatory disease, a diagnosis of non-gonococcal urethritis) as determined by study PI; or who were not prescribed an antibiotic with activity against gonorrhea on the day of clinic visit in the absence of a positive test result for gonorrhea or clinical syndrome for which the antibiotics are indicated.
Time frame: Day 1
Proportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results
The proportion of point of care gram stain results (control arm) or rapid test results (intervention arm) that were unavailable or invalid (unable to be read or provided an error message) at the time of the clinic visit.
Time frame: Day 1
Clinic Provider Perspectives on Rapid STI Testing
Clinic provider perspectives will be elicited during a focus group discussion at the conclusion of the clinical study.
Time frame: at study completion: 12 months
| Milestone | Standard of Care | Rapid STI Test |
|---|---|---|
| Started | 49 | 49 |
| Completed | 49 | 49 |
| Not completed | 0 | 0 |
The investigators will compare the mean antibiotic days of therapy (DOT) administered per patient at the time of initial ciinical visit when evaluated with either point-of-care gram stain or rapid 30-minute desktop test.
| Antibiotic days of therapy (DOT) | Standard of Care | Rapid STI Test |
|---|---|---|
| Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis | 7 (0 to 8) | 1 (0 to 7) |
The investigators will compare visit duration between participants randomized to the point-of-care test and those to the 30-minute desktop test. Participant visit duration will be calculated as the difference between when the participant enters the exam room and when they check out of the clinic, in minutes.
| Minutes | Standard of Care | Rapid STI Test |
|---|---|---|
| Participant Visit Duration | 57 (45 to 69) | 87 (72 to 97) |
The investigators will compare the time taken to process clinical specimen using either the point-of-care gram stain or rapid 30-minute desktop test. The provider processing the samples will record the start and end times on a time sheet, and the sample processing time will be calculated as the difference between those entries, in minutes.
No measurements were reported for this outcome.
The investigators will compare time from specimen collection to availability of test result between the point-of-care gram stain or rapid 30-minute desktop test. Providers will record time of specimen collection and time of result (for point of care gram stain), time of result for the rapid desktop platform will be extracted from the platform; time to result will be calculated as the difference between those times, in minutes.
| Minutes | Standard of Care | Rapid STI Test |
|---|---|---|
| Time to Result | 6.5 (5 to 9) | 34 (33 to 36) |
Proportion of participants in each arm who recevied gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was positive for gonorrhea, or who did not receive gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was negative for gonorrhea
| Participants | Standard of Care | Rapid STI Test |
|---|---|---|
| Test-concordant Antibiotic Use for Gonorrhea | 41 | 46 |
Proportion of participants in each arm who were prescribed an antibiotic with activity against gonorrhea on the day of clinic visit, either for a positive test result or for a clinical syndrome for which the antibiotics are indicated (e.g., a clinical diagnosis of pelvic inflammatory disease, a diagnosis of non-gonococcal urethritis) as determined by study PI; or who were not prescribed an antibiotic with activity against gonorrhea on the day of clinic visit in the absence of a positive test result for gonorrhea or clinical syndrome for which the antibiotics are indicated.
| Participants | Standard of Care | Rapid STI Test |
|---|---|---|
| Diagnosis-concordant Antibiotic Use for Gonorrhea | 43 | 48 |
The proportion of point of care gram stain results (control arm) or rapid test results (intervention arm) that were unavailable or invalid (unable to be read or provided an error message) at the time of the clinic visit.
| Participants | Standard of Care | Rapid STI Test |
|---|---|---|
| Proportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results | 4 | 0 |
Clinic provider perspectives will be elicited during a focus group discussion at the conclusion of the clinical study.
Results for this outcome have not been posted.
Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | 0/49 (0%) | 0/49 (0%) | 0/49 (0%) |
| Rapid STI Test | 0/49 (0%) | 0/49 (0%) | 0/49 (0%) |
| Age, Continuous(years) | Standard of Care | Rapid STI Test | Total |
|---|---|---|---|
| Median | 28 (24 to 35) | 31 (26 to 39) | 29.5 (25 to 39) |
| Sex/Gender, Customized(Participants) | Standard of Care | Rapid STI Test | Total |
|---|---|---|---|
| Cisgender male | 34 | 28 | 62 |
| Cisgender female | 13 | 19 | 32 |
| Transgender/nonbinary | 1 | 2 | 3 |
| Other | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Standard of Care | Rapid STI Test | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 7 | 17 |
| Not Hispanic or Latino | 30 | 35 | 65 |
| Unknown or Not Reported | 9 | 7 | 16 |
| Race (NIH/OMB)(Participants) | Standard of Care | Rapid STI Test | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 5 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 12 | 20 |
| White | 26 | 18 | 44 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 12 | 11 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Jun 2024, 15 months.
Results were first posted in Sep 2025, 1 year 2 months after primary completion.
Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's 15 months is below that.
Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
Massachusetts General Hospital →